A Prospective, Phase 3, Open Label, International Multicenter Study on Efficacy and Safety of Prophylaxis With rVWF in Severe Von Willebrand Disease

Trial Profile

A Prospective, Phase 3, Open Label, International Multicenter Study on Efficacy and Safety of Prophylaxis With rVWF in Severe Von Willebrand Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Factor VIII (Primary) ; Vonicog alfa (Primary)
  • Indications Von Willebrand disease
  • Focus Therapeutic Use
  • Acronyms rVWF IN PROPHYLAXIS
  • Sponsors Baxalta
  • Most Recent Events

    • 17 Feb 2017 Status changed to recruiting.
    • 28 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top